Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trial Program of a Medical Instrument Product.

Next Previous
Search
Trial Profile

Clinical Trial Program of a Medical Instrument Product.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Aspirin; Bivalirudin; Clopidogrel; Heparin
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Myocardial ischaemia; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms SEEDS

    • Most Recent Events

    • 01 Mar 2017 Status changed from recruiting to active, no longer recruiting, according to the results published in the Catheterization and Cardiovascular Interventions
    • 01 Mar 2017 Results of SEEDS substudy (n=1851) assessing SRI as a predictor of adverse ischemic events, published in the Catheterization and Cardiovascular Interventions
    • 07 Nov 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2010).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top